Malaria has a high prevalence in Sub-Saharan Africa and is a major public health problem in Nigeria. It accounts for over 60% outpatient visits and 30% hospital admissions.
The disease has negatively impacted the Nigerian economy with billions of Naira lost to it as cost of treatment and loss in man-hours. No wonder GlaxoSmithKline Nigeria partnered with the Lagos State Medicine Dealers Association (LSMDA) to join the fight to help end Malaria for good.
To mark this year’s World Malaria Day, the two organizations came together at the National Stadium, Surulere, Lagos, to commemorate the 2016 World Malaria Day, and to reaffirm Colart and Panadol as an effective and rational combination medication to treat the disease and relieve patients of pains and fever associated with malaria.
Colart, an antimalarial, and Panadol, an analgesic, are medicines produced by GSK, one of the world’s leading research-based pharmaceutical and healthcare companies, renowned for producing quality medicines.
Speaking at the event which drew Medicine Dealers from far and near, the Marketing Director for GSK Consumer Health, Kerry Alexander, said;
“Malaria is a huge burden in Africa, with more than 500,000 deaths every year. GSK is joining the campaign to ‘End Malaria for Good’ with two of its products: Colart, an anti-malarial that kills the malaria parasite, and Panadol, an analgesic that helps treat symptoms associated with pain and fever. This allows patients to feel better whilst they get better.”
She further reaffirmed GSK’s commitment to eradicate Malaria in Nigeria, in that, for over 40 years, GSK has continued to impact society, improve the quality of human lives of the Nigerian people by enabling them ‘to do more, feel better and live longer’.